<DOC>
	<DOCNO>NCT00556504</DOCNO>
	<brief_summary>The primary objective study evaluate effectiveness TCM-700C add-on treatment combination drug therapy ( Peginterferon α-2b plus Ribavirin ) patient genotype 1 chronic hepatitis C infection . This demonstrate high sustained virologic response rate , define absence detectable HCV RNA 24 week termination combinational drug treatment , compare placebo add-on .</brief_summary>
	<brief_title>The Effects Adding TCM-700C Standard Combination Treatment Patients With Genotype 1 Hepatitis C Infection</brief_title>
	<detailed_description>This randomize , double-blind , placebo control , parallel-group , Phase 2 study evaluate effect add Chinese formulation ( TCM-700C ) standard combination treatment patient Genotype 1 hepatitis C infection . Patients screen within 4 week receive first study drug dose . Eligible patient baseline stratify accord baseline HCV RNA ( ≤800,000 IU/ml v &gt; 800,000 IU/ml ) randomize equal chance receive either TCM-700C placebo add-on combination drug therapy . The combination drug therapy peginterferon α-2b ( PEG-INTRON® , Schering-Plough ) 1.5 micrograms/kg weekly injection 48 week plus oral ribavirin ( REBETOL® , Shering-Plough ) 1000mg-1200mg daily 48 week . The add-on treatment TCM-700C placebo give 2 tablet thrice daily 48 week . During 48 week treatment period 24 week untreated follow-up , patient assess regular interval safety efficacy week 2 , 4 , 8 , 12 , 16 every 8 week thereafter study completion . Patients prematurely discontinue test drug therapy laboratory examination re-taken week patient discontinue study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>HCV strain confirm genotype I ; Elevated ALT ( ≥1.5 x upper limit normal ) last 6 month Females childbearing potential negative serum pregnancy test Subject must willing sign write informed consent Subject must willing able adhere dose visit schedule . Serum AFP level &gt; 400 ng/ml Liver biopsy within 12 month prior study entry show liver cirrhosis METAVIR system fibrosis score 34 , hepatocellular carcinoma ( HCC ) ; Coinfection hepatitis B virus ( HBV ) ; AntiHIV positive ;</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>add-on treatment</keyword>
	<keyword>botanical drug</keyword>
	<keyword>HCV genotype 1</keyword>
	<keyword>TCM-700C</keyword>
	<keyword>genotype I</keyword>
</DOC>